Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Long-Term Deferred Tax (2019 - 2025)

Autolus Therapeutics' Long-Term Deferred Tax history spans 7 years, with the latest figure at $3.6 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 9.91% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $3.6 million, up 9.91%, while the annual FY2025 figure was $3.6 million, 9.91% up from the prior year.
  • Long-Term Deferred Tax reached $3.6 million in Q4 2025 per AUTL's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $3.6 million in Q4 2025 to a low of $1.8 million in Q4 2021.
  • Average Long-Term Deferred Tax over 5 years is $2.7 million, with a median of $2.4 million recorded in 2025.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 47.54% in 2023, then dropped 29.51% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $1.8 million in 2021, then rose by 13.69% to $2.1 million in 2022, then soared by 47.54% to $3.1 million in 2023, then grew by 5.75% to $3.2 million in 2024, then rose by 9.91% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Long-Term Deferred Tax are $3.6 million (Q4 2025), $2.4 million (Q3 2025), and $2.4 million (Q2 2025).